HEADER HYDROLASE/HYDROLASE INHIBITOR 01-NOV-11 3UFN TITLE CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL TITLE 2 ISOLATE PR20 IN COMPLEX WITH SAQUINAVIR COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 501-599; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.AGNISWAMY,S.CHEN-HSIANG,A.ANIANA,J.M.SAYER,J.M.LOUIS,I.T.WEBER REVDAT 2 17-OCT-12 3UFN 1 JRNL REVDAT 1 28-MAR-12 3UFN 0 JRNL AUTH J.AGNISWAMY,C.H.SHEN,A.ANIANA,J.M.SAYER,J.M.LOUIS,I.T.WEBER JRNL TITL HIV-1 PROTEASE WITH 20 MUTATIONS EXHIBITS EXTREME RESISTANCE JRNL TITL 2 TO CLINICAL INHIBITORS THROUGH COORDINATED STRUCTURAL JRNL TITL 3 REARRANGEMENTS. JRNL REF BIOCHEMISTRY V. 51 2819 2012 JRNL REFN ISSN 0006-2960 JRNL PMID 22404139 JRNL DOI 10.1021/BI2018317 REMARK 2 REMARK 2 RESOLUTION. 1.45 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.45 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.176 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.173 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.225 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1592 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 30386 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.161 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.158 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.209 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1345 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 26130 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1518 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 100 REMARK 3 SOLVENT ATOMS : 126 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1742.53 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 0.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 6 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 15973 REMARK 3 NUMBER OF RESTRAINTS : 20318 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 ANGLE DISTANCES (A) : 0.029 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.036 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.052 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.064 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.027 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.004 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.060 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.081 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC REFINEMENT REDUCED FREE R REMARK 3 (NO CUTOFF) BY ? REMARK 4 REMARK 4 3UFN COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-NOV-11. REMARK 100 THE RCSB ID CODE IS RCSB068694. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-FEB-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 3.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : SI220 REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 31811 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.450 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.83 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.97 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 6.20 REMARK 200 R MERGE FOR SHELL (I) : 0.17400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 10.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.47 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.06 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.93M SODIUM CHLORIDE AND 30MM CITRATE REMARK 280 -PHOSPHATE BUFFER, PH 3.8, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 14.41500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 46.58350 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 33.13000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 46.58350 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 14.41500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 33.13000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5800 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 10040 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -39.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 NE - CZ - NH1 ANGL. DEV. = 3.7 DEGREES REMARK 500 ARG A 8 NE - CZ - NH2 ANGL. DEV. = -4.0 DEGREES REMARK 500 ARG A 41 NE - CZ - NH1 ANGL. DEV. = -3.6 DEGREES REMARK 500 ARG B 8 NE - CZ - NH1 ANGL. DEV. = 3.5 DEGREES REMARK 500 ARG B 8 NE - CZ - NH2 ANGL. DEV. = -5.2 DEGREES REMARK 500 ARG B 87 NE - CZ - NH1 ANGL. DEV. = 3.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 35 53.16 -109.05 REMARK 500 ASP B 35 72.64 47.79 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ILE B 66 ALA B 67 -72.21 REMARK 500 REMARK 500 REMARK: NULL REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: (2S)-N-[(2S,3R)-4-[(2S,3S,4AS,8AS)-3-(TERT- REMARK 630 BUTYLCARBAMOYL)-3,4,4A,5,6,7,8,8A-OCTAHYDRO-1H-ISOQUINOLIN-2-YL]- REMARK 630 3-HYDROXY-1-PHENYL-BUTAN-2-YL]-2-(QUINOLIN-2-YLCARBONYLAMINO) REMARK 630 BUTANEDIAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 ROC A 401 REMARK 630 ROC A 402 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: QNC ASN HP0 NTB REMARK 630 DETAILS: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ROC A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ROC A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 100 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 101 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3UCB RELATED DB: PDB REMARK 900 RELATED ID: 3UF3 RELATED DB: PDB REMARK 900 RELATED ID: 3UHL RELATED DB: PDB DBREF 3UFN A 1 99 UNP P03367 POL_HV1BR 501 599 DBREF 3UFN B 1 99 UNP P03367 POL_HV1BR 501 599 SEQADV 3UFN LYS A 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 3UFN PHE A 10 UNP P03367 LEU 510 ENGINEERED MUTATION SEQADV 3UFN VAL A 13 UNP P03367 ILE 513 ENGINEERED MUTATION SEQADV 3UFN VAL A 15 UNP P03367 ILE 515 ENGINEERED MUTATION SEQADV 3UFN ASN A 30 UNP P03367 ASP 530 ENGINEERED MUTATION SEQADV 3UFN ILE A 32 UNP P03367 VAL 532 ENGINEERED MUTATION SEQADV 3UFN PHE A 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 3UFN ASP A 35 UNP P03367 GLU 535 ENGINEERED MUTATION SEQADV 3UFN ILE A 36 UNP P03367 MET 536 ENGINEERED MUTATION SEQADV 3UFN ASN A 37 UNP P03367 SER 537 ENGINEERED MUTATION SEQADV 3UFN VAL A 47 UNP P03367 ILE 547 ENGINEERED MUTATION SEQADV 3UFN LEU A 54 UNP P03367 ILE 554 ENGINEERED MUTATION SEQADV 3UFN GLU A 58 UNP P03367 GLN 558 ENGINEERED MUTATION SEQADV 3UFN VAL A 62 UNP P03367 ILE 562 ENGINEERED MUTATION SEQADV 3UFN PRO A 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 3UFN ALA A 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 3UFN VAL A 71 UNP P03367 ALA 571 ENGINEERED MUTATION SEQADV 3UFN VAL A 84 UNP P03367 ILE 584 ENGINEERED MUTATION SEQADV 3UFN ASP A 88 UNP P03367 ASN 588 ENGINEERED MUTATION SEQADV 3UFN THR A 89 UNP P03367 LEU 589 ENGINEERED MUTATION SEQADV 3UFN MET A 90 UNP P03367 LEU 590 ENGINEERED MUTATION SEQADV 3UFN ALA A 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQADV 3UFN LYS B 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 3UFN PHE B 10 UNP P03367 LEU 510 ENGINEERED MUTATION SEQADV 3UFN VAL B 13 UNP P03367 ILE 513 ENGINEERED MUTATION SEQADV 3UFN VAL B 15 UNP P03367 ILE 515 ENGINEERED MUTATION SEQADV 3UFN ASN B 30 UNP P03367 ASP 530 ENGINEERED MUTATION SEQADV 3UFN ILE B 32 UNP P03367 VAL 532 ENGINEERED MUTATION SEQADV 3UFN PHE B 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 3UFN ASP B 35 UNP P03367 GLU 535 ENGINEERED MUTATION SEQADV 3UFN ILE B 36 UNP P03367 MET 536 ENGINEERED MUTATION SEQADV 3UFN ASN B 37 UNP P03367 SER 537 ENGINEERED MUTATION SEQADV 3UFN VAL B 47 UNP P03367 ILE 547 ENGINEERED MUTATION SEQADV 3UFN LEU B 54 UNP P03367 ILE 554 ENGINEERED MUTATION SEQADV 3UFN GLU B 58 UNP P03367 GLN 558 ENGINEERED MUTATION SEQADV 3UFN VAL B 62 UNP P03367 ILE 562 ENGINEERED MUTATION SEQADV 3UFN PRO B 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 3UFN ALA B 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 3UFN VAL B 71 UNP P03367 ALA 571 ENGINEERED MUTATION SEQADV 3UFN VAL B 84 UNP P03367 ILE 584 ENGINEERED MUTATION SEQADV 3UFN ASP B 88 UNP P03367 ASN 588 ENGINEERED MUTATION SEQADV 3UFN THR B 89 UNP P03367 LEU 589 ENGINEERED MUTATION SEQADV 3UFN MET B 90 UNP P03367 LEU 590 ENGINEERED MUTATION SEQADV 3UFN ALA B 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO PHE VAL THR VAL SEQRES 2 A 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASN THR ILE PHE GLU ASP ILE ASN LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE LEU LYS VAL ARG GLU TYR ASP GLN VAL PRO ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN VAL ILE GLY ARG ASP THR MET THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO PHE VAL THR VAL SEQRES 2 B 99 LYS VAL GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASN THR ILE PHE GLU ASP ILE ASN LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET VAL GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE LEU LYS VAL ARG GLU TYR ASP GLN VAL PRO ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS VAL ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN VAL ILE GLY ARG ASP THR MET THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET ROC A 401 49 HET ROC A 402 49 HET CL B 100 1 HET CL B 101 1 HETNAM ROC (2S)-N-[(2S,3R)-4-[(2S,3S,4AS,8AS)-3-(TERT- HETNAM 2 ROC BUTYLCARBAMOYL)-3,4,4A,5,6,7,8,8A-OCTAHYDRO-1H- HETNAM 3 ROC ISOQUINOLIN-2-YL]-3-HYDROXY-1-PHENYL-BUTAN-2-YL]-2- HETNAM 4 ROC (QUINOLIN-2-YLCARBONYLAMINO)BUTANEDIAMIDE HETNAM CL CHLORIDE ION HETSYN ROC FORTOVASE; SAQUINAVIR,RO 31-8959 FORMUL 3 ROC 2(C38 H50 N6 O5) FORMUL 5 CL 2(CL 1-) FORMUL 7 HOH *126(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLN A 92 GLY A 94 5 3 SHEET 1 A 4 GLN A 2 THR A 4 0 SHEET 2 A 4 THR A 96 ASN A 98 -1 SHEET 1 B 8 LYS A 43 GLY A 48 0 SHEET 2 B 8 PHE A 53 ILE A 66 -1 O GLU A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O VAL A 71 N ILE A 64 SHEET 4 B 8 ILE A 32 PHE A 33 1 N PHE A 33 O LEU A 76 SHEET 5 B 8 VAL A 84 ILE A 85 -1 O VAL A 84 N ILE A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 PHE A 10 VAL A 15 -1 N VAL A 13 O LYS A 20 SHEET 8 B 8 PHE A 53 ILE A 66 -1 O GLU A 65 N LYS A 14 SITE 1 AC1 20 ASP A 25 GLY A 27 ALA A 28 ASP A 29 SITE 2 AC1 20 ASN A 30 VAL A 47 GLY A 48 GLY A 49 SITE 3 AC1 20 ILE A 50 PRO A 81 ROC A 402 HOH A 522 SITE 4 AC1 20 HOH A 525 ASP B 25 GLY B 27 GLY B 48 SITE 5 AC1 20 GLY B 49 ILE B 50 VAL B 82 CL B 100 SITE 1 AC2 18 ARG A 8 PHE A 10 TRP A 42 LYS A 55 SITE 2 AC2 18 VAL A 82 ROC A 401 HOH A 521 HOH A 548 SITE 3 AC2 18 HOH A 561 HOH A 563 ARG B 8 PHE B 10 SITE 4 AC2 18 GLU B 21 GLY B 27 ASP B 29 PRO B 81 SITE 5 AC2 18 VAL B 82 HOH B 237 SITE 1 AC3 3 ROC A 401 ASP B 29 ASN B 30 SITE 1 AC4 3 ARG A 8 GLU B 21 HOH B 237 CRYST1 28.830 66.260 93.167 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.034686 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015092 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010733 0.00000 MASTER 275 0 4 2 10 0 12 6 0 0 0 16 END